Ignite Creation Date:
2024-10-26 @ 3:37 PM
Last Modification Date:
2024-10-26 @ 3:37 PM
Study NCT ID:
NCT06540326
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-07-22
Brief Title:
Clinical Study of Second-line Treatment in Advanced Colorectal Cancer With Chemotherapy With Bevacizumab or Cetuximab
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Clinical Study of Second-line Treatment of Patients With Advanced Colorectal Cancer With Irinotecan Liposome II Fluorouracil in Combination With Bevacizumab or Cetuximab
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Guidelines recommend FOLFIRI in combination with bevacizumab or cetuximab as a treatment option for advanced second-line colorectal cancer and this study explores the efficacy and safety of a clinical study of liposomal irinotecan II fluorouracil in combination with bevacizumab or cetuximab for the second-line treatment of patients with advanced colorectal cancer
Detailed Description:
Guidelines recommend FOLFIRI in combination with bevacizumab or cetuximab as a treatment option for advanced second-line colorectal cancer Liposomal irinotecan II compared with ordinary irinotecan can improve efficacy and safety This study explores the efficacy and safety of a clinical study of liposomal irinotecan II fluorouracil in combination with bevacizumab or cetuximab for the second-line treatment of patients with advanced colorectal cancer
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None